HDSA’s 33rd Annual Convention in Los Angeles from June 7th-9th included the 2018 Research Forum, where ten speakers collaborated to tell a story about the HD gene and the continued work towards designing and testing a huntingtin-lowering therapy. Check it out here and stay tuned for a recap of research news at Convention!   CRISPR research…

This week we’re hosting the 33rd Annual HDSA Convention in Los Angeles, California. Tune in to the livestream of our Research Forum this Saturday, June 9th beginning at 9 am PDT (12 pm EDT). Sessions will also be recorded for later viewing. Visit HDSA.org/convention for more info and follow us on social media with #HDSAConvention.

The prestigious journal Nature publishes both research reports and journalistic articles, and is widely read by scientists and non-scientists. This week, Nature published an Outlook edition specifically related to Huntington’s disease. The articles explore how scientists are approaching the biology of HD and Juvenile HD, invite perspectives from at-risk and affected individuals, discuss huntingtin-lowering therapies…

If you are negative for the HD gene, currently participate in Enroll-HD, and will be attending HDSA’s Convention in June, consider volunteering for a research study on Friday, June 8th at the Convention hotel. Dr. Madeleine Sharp is studying how HD affects cognition and she is looking for control participants (negative for HD) to contribute…

The 2018 HDSA Berman-Topper fellowship has been awarded to Dr. Rachel Harding for her proposal entitled “Structural and biophysical investigations of DNA and DNA repair protein interactions with huntingtin.” Check out the HDSA press release here. Dr. Harding will conduct the research at the University of Toronto under the guidance of Dr. Cheryl Arrowsmith and…

Join the #HDSAFamily as we turn up the global volume on HD awareness. Visit www.HDSA.org/letstalkaboutHD for more info. Don’t forget to share your stories about participating in HD research! An international Initiative to develop stem cell therapeutics for Huntington’s Disease Research into stem cell treatments for Huntington’s Disease has advanced considerably over the past decade….

On April 24th, 2018, Ionis Pharmaceuticals made an announcement about the Phase 1/2 clinical trial of their huntingtin-lowering drug, IONIS-HTTRx (RG6042). As we mentioned last week, the news was shared publicly in a press release and the data was highlighted at the American Academy of Neurology (AAN) Annual Meeting. To clarify the meaning of the…

Huntington’s disease was featured this week at the American Academy of Neurology (AAN) Conference, where 12,000 medical professionals gathered for a yearly forum on neurology research. The mainstage presentation, in front of a huge audience of doctors and scientists, featured the most recent positive results from the Phase 1b/2a trial of the huntingtin-lowering drug from…

This week HDSA is celebrating National Volunteer Appreciation Week. This goes for research, too! We’d like to express our heartfelt thanks to everyone who lends a hand to make HDSA’s work possible and contributes to the progress of HD science. Our understanding and our ability to treat HD is constantly expanding because of extraordinary volunteers…

Huntington’s disease research plays a big role at our annual Convention, which is taking place this year on June 7th-9th in Los Angeles, California. We’ll have talks and poster sessions presented by HDSA-funded scientists including our Donald King Summer Research Fellows, Human Biology Project Fellows, and recipients of the Berman-Topper Career Development Fellowship. Other research…